Morocco Slashes Prices on 34 Cancer and Cardiovascular Drugs, Including Breast Cancer Treatment Ibrance

The Ministry of Health is expanding the list of drugs affected by the price review. It published in the Official Bulletin of October 1, 2020 the list of drugs (original and generic) whose price has been revised downwards. These are 34 drugs whose initial public selling prices were between 29 and 42,562 dirhams. They have seen reductions of 1 to more than 20,000 dirhams.

The new list is added to the previous list of more than 3,600 drugs whose prices have been reduced following the application of the provisions of Decree 2.13.852, published on December 19, 2013, on the conditions and procedures for setting drug prices.

"Ibrance", prescribed in breast cancer therapy, has indeed benefited from a significant reduction. Following an initial price reduction a year earlier from 52,484 to 42,562 dirhams, the Ministry of Health has set its public selling price at 24,123 dirhams. A price that is now aligned with that of France.

This reduction is indeed part of the implementation of the national drug policy aimed at promoting citizens’ access to medicines, relieving them of medical coverage expenses. Equitable access to quality treatments at reasonable prices is also a priority.